Recognizing the importance of respiratory syncytial virus in chronic obstructive pulmonary disease

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 6, Issue 1, 2009, Pages 64-75

  Ramaswamy, Murali ^a   Groskreutz, Dayna J ^b   Look, Dwight C ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Acute exacerbation; Antiviral immunity; COPD; RSV; Viral diagnosis

Indexed keywords

CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; DISEASE PREDISPOSITION; HEALTH CARE COST; HOST RESISTANCE; HUMAN; IMMUNITY; INFECTION SENSITIVITY; MORBIDITY; MORTALITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT INFECTION; REVIEW; VIRUS DETECTION;

DISEASE SUSCEPTIBILITY; HUMANS; IMMUNITY, INNATE; INFLUENZA, HUMAN; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS;

EID: 61649106523     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.1080/15412550902724024     Document Type: Review

References (138)

1. Jemal A, Ward E, Hao Y, Thun M. Trends in the leading causes of death in the United States, 1970-2002. JAMA 2005; 294:1255-1259.
2. Roman J, Perez RL. COPD in VA hospitals. Clinical Cornerstone 2003; 5:37-44.
3. Donaldson GC, Wedzicha JA. COPD exacerbations: 1. Epidemiology. Thorax 2006; 61:164-168.
4. Sapey E, Stockley RA. COPD exacerbations: 2. Aetiology. Thorax 2006; 61:250-258.
5. Rohde G, Wiethege A, Borg I, Kauth M, Bauer TT, Gillissen A, Bufe A, Schultze-Werninghaus G. Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalisation: a case-control study. Thorax 2003; 58:37-42.
6. Beckham JD, Cadena A, Lin J, Piedra PA, Glezen WP, Greenberg SB, Atmar RL. Respiratory viral infections in patients with chronic obstructive pulmonary disease. J Infect 2005; 50:322-330.
7. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N Eng J Med 2005; 352:1749-1759.
8. Falsey AR, Criddle MC, Walsh EE. Detection of respiratory syncytial virus and human metapneumovirus by reverse transcription polymerase chain reaction in adults with and without respiratory illness. J Clin Virol 2006; 35:46-50.
9. Falsey AR, Formica MA, Hennessey PA, Criddle MM, Sullender WM, Walsh EE. Detection of respiratory syncytial virus in adults with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 173:639-643.
10. Hall CB. Respiratory syncytial virus and parainfluenza virus. N Eng J Med 2001; 344:1917-1928.
11. Chanock R, Roizman B, Myers R. Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). I. Isolation, properties and characterization. Am J Hyg 1957; 66:281-290.
12. Louie JK, Hacker JK, R. G, Mark J, Maselli JH, Yagi S, Drew WL. Characterization of viral agents causing acute respiratory infection in a San Francisco universitymedical center clinic during the influenza season. Clin Infect Dis 2005; 41:822-828.
13. Johnston SL, Pattemore PK, Sanderson G, Smith S, Lampe F, Josephs L, Symington P, O'Toole S, Myint SH, Tyrrell DAJ, Holgate ST. Community study of role of viral infections in exacerbations of asthma in 9-11 year old children. Br Med J 1995; 310:1225-1228.
14. Nicholson KG, Kent J, Ireland DC. Respiratory viruses and exacerbations of asthma in adults. Br Med J 1993; 307:982-986.
15. Soler N, Torres A, Ewig S, Gonzalez J, Celis R, El-Ebiary M, Hernandez C, Rodriguez-Roisin R. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. Am J Respir Crit Care Med 1998; 157:1498-1505.
16. Ko FW, Ip M, Chan PK, Fok JP, Chan MC, Ngai JC, Chan DP, Hui DS. A 1-year prospective study of the infectious etiology in patients hospitalized with acute exacerbations of COPD. Chest 2007; 131:44-52.
17. Cameron RJ, de Wit D, Welsh TN, Ferguson J, Grissell TV, Rye PJ. Virus infection in exacerbations of chronic obstructive pulmonary disease requiring ventilation. Intensive Care Med 2006; 32:968-970.
18. Falsey AR, Formica MA, Treanor JJ, Walsh EE. Comparison of quantitative reverse transcription-PCR to viral culture for assessment of respiratory syncytial virus shedding. J Clin Microbiol 2003; 41:4160-4165.
19. Borg I, Rohde G, Loseke S, Bittscheidt J, Schultze-Werninghaus G, Stephan V, Bufe A. Evaluation of a quantitative real-time PCR for the detection of respiratory syncytial virus in pulmonary diseases. Eur Resp J 2003; 21:944-951.
20. Wilkinson TM, Donaldson GC, Johnston SL, Openshaw PJ, Wedzicha JA. Respiratory syncytial virus, airway inflammation, and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 173:871-876.
21. Sethi S, Evans N, Grant BJ, Murphy TF. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Eng J Med 2002; 347:465-471.
22. Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. Eur Resp J 2003; 21 (Suppl 41):46s-53s.
23. Sunyer J, Sáez M, Murillo C, Castellsague J, Martínez F, Antó JM. Air pollution and emergency room admissions for chronic obstructive pulmonary disease: a 5-year study. Am J Epidemiol 1993; 137:701-705.
24. Ball P. Epidemiology and treatment of chronic bronchitis and its exacerbations. Chest 1995; 108:43S-52S.
25. Connors AFJ, Dawson NV, Thomas C, Harrell FEJ, Desbiens N, Fulkerson WJ, Kussin P, Bellamy P, Goldman L, Knaus WA. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (study to understand prognoses and preferences for outcomes and risks of treatments). Am J Respir Crit Care Med 1996; 154:959-967.
26. Walsh EE, Peterson DR, Falsey AR. Risk factors for severe respiratory syncytial virus infection in elderly persons. J Infect Dis 2004; 189:233-238.
27. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, Fukuda K. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003; 289:179-186.
28. Lee FEH, Walsh EE, Falsey AR, Betts RF, Treanor JJ. Experimental infection of humans with A2 respiratory syncytial virus. Antiviral Res 2004; 63:191-196.
29. Glezen P, Denny FW. Epidemiology of acute lower respiratory disease in children. N Engl J Med 1973; 288:498-505.
30. Upshur REG, Moineddin R, Crighton EJ, Mamdani M. Interactions of viral pathogens on hospital admissions for pneumonia, croup and chronic obstructive pulmonary diseases: Results of amultivariate time-series analysis. Epidemiol Infect 2006; 134:1174-1178.
31. Mullooly JP, Bridges CB, Thompson WW, Chen J, Weintraub E, Jackson LA, Black S, Shay DK, Vaccine Safety Datalink Adult Working Group. Influenza- and RSV-associated hospitalizations among adults. Vaccine 2007; 25:846-855.
32. Dakhama A, Vitalis TZ, Hegele RG. Persistence of respiratory syncytial virus (RSV) infection and development of RSV-specific IgG1 response in a guinea-pig model of acute bronchiolitis. Eur Respir J 1997; 10:20-26.
33. Bramley AM, Vitalis TZ, Wiggs BR, Hegele RG. Effects of respiratory syncytial virus persistence on airway responsiveness and inflammation in guinea-pigs. Eur Resp J 1999; 14:1061-1067.
34. Schwarze J, O'Donnell DR, Rohwedder A, Openshaw PJ. Latency and persistence of respiratory syncytial virus despite T cell immunity. Am J Respir Crit Care Med 2004; 169:801-805.
35. Cubie HA, Duncan LA, Marshall LA, Smith NM. Detection of respiratory syncytial virus nucleic acid in archival postmortem tissue from infants. Pediatr Pathol Lab Med 1997; 17:927-938.
36. Hogg JC. Role of latent viral infections in chronic obstructive pulmonary disease and asthma. Am J Respir Crit Care Med 2001; 164:S71-S75.
37. Seemungal T, Harper-Owen R, Bhowmik A, Moric I, Sanderson G, Message S, Maccallum P, Meade TW, Jeffries DJ, Johnston SL, Wedzicha, JA. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164:1618-1623.
38. Greenberg SB, Allen M, Wilson J, Atmar RL. Respiratory viral infections in adults with and without chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 162:167-173.
39. Croxton TL, Weinmann GG, Senior RM, Wise RA, Crapo JD, Buist AS. Clinical research in chronic obstructive pulmonary disease - needs and opportunities. Am J Respir Crit Care Med 2003; 17:1142-1149.
40. Robbins CS, Dawe DE, Goncharova SI, Pouladi MA, Drannik AG, Swirski FK, Cox G, Stämpfli MR. Cigarette smoke decreases pulmonary dendritic cells and impacts antiviral immune responsiveness. Am J Respir Cell Mol Biol 2004; 30:202-211.
41. Robbins CS, Bauer CM, Vujicic N, Gaschler GJ, Lichty BD, Brown EG, Stämpfli MR. Cigarette smoke impacts immune inflammatory responses to influenza inmice. Am J Respir Crit Care Med 2006; 174:1342-1351.
42. Huchon GJ, Russell JA, Barritault LG, Lipavsky A, Murray JF. Chronic air-flow limitation does not increase respiratory epithelial permeability assessed by aerosolized solute, but smoking does. Am Rev Respir Dis 1984; 130:457-460.
43. Monick MM, Yarovinsky TO, Powers LS, Butler NS, Carter AB, Gudmundsson G, Hunninghake GW. Respiratory syncytial virus up-regulates TLR4 and sensitizes airway epithelial cells to endotoxin. J Biol Chem 2003; 278:53035-53044.
44. Tal G, Mandelberg A, Dalal I, Cesar K, Somekh E, Tal A, Oron A, Itskovich S, Ballin A, Houri S, Beigelman A, Lider O, Rechavi G, Amariglio N. Association between common toll-like receptor 4 mutations and severe respiratory syncytial virus disease. J Infect Dis 2004; 189:2057-2063.
45. Puthothu B, Forster J, Heinzmann A, Krueger M. TLR-4 and CD14 polymorphisms in respiratory syncytial virus associated disease. Dis Markers 2006; 22:303-308.
46. Hull J, Thomson A, Kwiatkowski D. Association of respiratory syncytial virus bronchiolitis with the interleukin 8 gene region in UK families. Thorax 2000; 55:1023-1027.
47. Löfgren J, Rämet M, Renko M, Marttila R, Hallman M. Association between surfactant protein A gene locus and severe respiratory syncytial virus infection in infants. J Infect Dis 2002; 185:283-289.
48. Lahti M, Lofgren J, Marttila R, Renko M, Klaavuniemi T, Haataja R, Ramet M, Hallman M. Surfactant protein D gene polymorphism associated with severe respiratory syncytial virus infection. Pediatr Res 2002; 51:696-699.
49. Hoebee B, Rietveld E, Bont L, Oosten M, Hodemaekers HM, Nagelkerke NJ, Neijens HJ, Kimpen JL, Kimman TG. Association of severe respiratory syncytial virus bronchiolitis with interleukin-4 and interleukin-4 receptor alpha polymorphisms. J Infect Dis 2003; 187:2-11.
50. Hull J, Rowlands K, Lockhart E, Moore C, Sharland M, Kwiatkowski D. Variants of the chemokine receptor CCR5 are associated with severe bronchiolitis caused by respiratory syncytial virus. J Infect Dis 2003; 188:904-907.
51. Hoebee B, Bont L, Rietveld E, van Oosten M, Hodemaekers HM, Nagelkerke NJ, Neijens HJ, Kimpen JL, Kimman TG. Influence of promoter variants of interleukin-10, interleukin-9, and tumor necrosis factor-alpha genes on respiratory syncytial virus bronchiolitis. J Infect Dis 2004; 189:239-247.
52. Puthothu B, Krueger M, Forster J, Heinzmann A. Association between severe respiratory syncytial virus infection and IL13/IL4 haplotypes. J Infect Dis 2006; 193:438-441.
53. Puthothu B, Krueger M, Heinze J, Forster J, Heinzmann A. Haplotypes of surfactant protein C are associated with common paediatric lung diseases. Pediatr Allergy Immunol 2006; 17:572-577.
54. Puthothu B, Forster J, Heinze J, Heinzmann A, Krueger M. Surfactant protein B polymorphisms are associated with severe respiratory syncytial virus infection, but not with asthma. BMC Pulm Med 2007; 7:6.
55. Krueger M, Puthothu B, Heinze J, Forster J, Heinzmann A. Genetic polymorphisms of adhesion molecules in children with severe RSV-associated diseases. Int J Immunogenet 2006; 33:233-235.
56. Becker S, Soukup J, Yankaskas JR. Respiratory syncytial virus infection of human primary nasal and bronchial epithelial cell cultures and bronchoalveolar macrophages. Am J Respir Cell Mol Biol 1992; 6:369-374.
57. Look DC, Walter MJ, Williamson MR, Pang L, You Y, Sreshta JN, Johnson JE, Zander DS, Brody SL. Effects of paramyxoviral infection on airway epithelial cell Foxj1 expression, ciliogenesis, and mucociliary function. Am J Pathol 2001; 159:2055-2069.
58. Johnson JE, Gonzales RA, Olson SJ, Wright PF, Graham BS. The histopathology of fatal untreated human respiratory syncytial virus infection. Mod Pathol 2007; 20:108-119.
59. Levin SJ. Bronchial epithelial cell-cytokine interactions in airway inflammation. J Invest Med 1995; 43:241-249.
60. Holtzman MJ, Look DC, Sampath D, Castro M, Koga T,Walter MJ. Control of epithelial immune-response genes and implications for airway immunity and inflammation. Proc Assoc Am Phys 1998; 110:1-11.
61. Look DC, Brody SL. Engineering viral vectors to subvert the airway defense response. Am J Respir CellMol Biol 1999; 20:1103-1106.
62. Noah TL, Becker S. Respiratory syncytial virus-induced cytokine production by a human bronchial epithelial cell line. Am J Physiol (Lung Cell Mol Physiol) 1993; 265:L472-L478.
63. Elias JA, Zheng T, Einarsson O, Landry M, Trow T, Rebert N, Panuska J. Epithelial interleukin-11 - regulation by cytokines, respiratory syncytial virus, and retinoic acid. J Biol Chem 1994; 269:22261-22268.
64. Stark JM, Godding V, Sedgwick JB, Busse WW. Respiratory syncytial virus infection enhances neutrophil and eosinophil adhesion to cultured respiratory epithelial cells - roles of CD18 and intercellular adhesion molecule-1. J Immunol 1996; 156:4774-4782.
65. Garofalo R, Mei F, Espejo R, Ye G, Haeberle H, Baron S, Ogra PL, Reyes VE. Respiratory syncytial virus infection of human respiratory epithelial cells up-regulates class I MHC expression through the induction of IFN-β and IL-1α. J Immunol 1996; 157:2506-2513.
66. Saito T, Deskin RW, Casola A, Haeberle H, Olszewska B, Ernst PB, Alam R, Ogra PL, Garofalo R. Respiratory syncytial virus induces selective production of the chemokine rantes by upper airway epithelial cells. J Infect Dis 1997; 175:497-504.
67. Becker S, Reed W, Henderson FW, Noah TL. RSV infection of human airway epithelial cells causes production of the β-chemokine RANTES. Am J Physiol (Lung Cell Mol Physiol) 1997; 272:L512-L520.
68. Olszewska-Pazdrak B, Casola A, Saito T, Alam R, Crowe SE, Mei F, Ogra PL, Garofalo RP. Cell-specific expression of RANTES, MCP-1, and MIP-1α by lower airway epithelial cells and eosinophils infected with respiratory syncytial virus. J Virol 1998; 72:4756-4764.
69. Koga T, Sardina E, Tidwell RM, Pelletier M, Look DC, Holtzman MJ. Virus-inducible expression of a host chemokine gene relies on replication-linked mRNA stabilization. Proc Natl Acad Sci USA 1999; 9(6):5680-5685.
70. Garofalo RP, Haeberle H. Epithelial regulation of innate immunity to respiratory syncytial virus. Am J Respir Cell Mol Biol 2000; 23:581-585.
71. Kao YJ, Piedra PA, Larsen GL, Colasurdo GN. Induction and regulation of nitric oxide synthase in airway epithelial cells by respiratory syncytial virus. Am J Respir Crit Care Med 2001; 163:532-539.
72. Milner ME, Monte SDL, Hutchins GM. Fatal respiratory syncytial virus infection in severe combined immunodeficiency syndrome. Am J Dis Child 1985; 139:1111-1114.
73. Cannon MJ, Openshaw PJM, Askonas BA. Cytotoxic T cells clear virus but augment lung pathology in mice infected with respiratory syncytial virus. J Exp Med 1988; 168:1163-1168.
74. Tang YW, Graham BS. T cell source of type I cytokines determines illness patterns in respiratory syncytial virus-infected mice. J Clin Invest 1997; 99:2183-2191.
75. Durbin JE, Johnson TR, Durbin RK, Mertz SE, Morotti RA, Peebles RS, Graham BS. The role of IFN in respiratory syncytial virus pathogenesis. J Immunol 2002; 168:2944-2951.
76. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem 1998; 67:227-264.
77. Ramaswamy M, Shi L, Monick MM, Hunninghake GW, Look DC. Specific inhibition of type I interferon signal transduction by respiratory syncytial virus. Am J Respir Cell Mol Biol 2004; 30:893-900.
78. Katze MG, He Y, Gale MJ. Viruses and interferon: a fight for supremacy. Nat Rev Immunol 2002; 2:675-687.
79. Look DC, Roswit WT, Frick AG, Gris-Alevy Y, Dickhaus DM, Walter MJ, Holtzman MJ. Direct suppression of Stat1 function during adenoviral infection. Immunity 1998; 9:871-880.
80. Taniguchi T, Takaoka A. A weak signal for strong responses: interferon-α/β revisited. Nature Rev 2001; 2:378-386.
81. Der SD, Zhou A, Williams BRG, Silverman RH. Identification of genes differentially regulated by interferon α, β, or γ using oligonucleotide arrays. Proc Natl Acad Sci USA 1998; 95:15623-15628.
82. Ramaswamy M, Shi L, Varga SM, Barik S, Behlke MA, Look DC. Respiratory syncytial virus nonstructural protein 2 specifically inhibits type I interferon signal transduction. Virology 2006; 344:328-339.
83. Bitko V, Shulyayeva O, Mazumder B, Musiyenko A, Ramaswamy M, Look DC, Barik S. Nonstructural proteins of respiratory syncytial virus suppress premature apoptosis by an NF-kappaB-dependent, interferon-independent mechanism and facilitate virus growth. J Virol 2007; 81:1786-1795.
84. ThomasKW,Monick MM, Staber JM, Yarovinsky T, Carter AB, Hunninghake GW. Respiratory syncytial virus inhibits apoptosis and induces NF-kappa B activity through a phosphatidylinositol 3-kinase-dependent pathway. J Biol Chem 2002; 277:492-501.
85. Monick MM, Cameron K, Staber J, Powers LS, Yarovinsky TO, Koland JG, Hunninghake GW. Activation of the epidermal growth factor receptor by respiratory syncytial virus results in increased inflammation and delayed apoptosis. J Biol Chem 2005; 280:2147-2158.
86. Groskreutz DJ, Monick MM, Yarovinsky TO, Powers LS, Quelle DE, Varga SM, Look DC, Hunninghake GW. Respiratory syncytial virus decreases p53 protein to prolong survival of airway epithelial cells. J Immunol 2007; 179:2741-2747.
87. Rudd BD, Burstein E,Duckett CS, Li X, Lukacs NW. Differential role for TLR3 in respiratory syncytial virus-induced chemokine expression. J Virol 2005; 79:3350-3357.
88. Groskreutz DJ, Monick MM, Powers LS, Yarovinsky TO, Look DC, HunninghakeGW. Respiratory syncytial virus induces TLR3 protein and protein kinase R, leading to increased double-stranded RNA responsiveness in airway epithelial cells. J Immunol 2006; 176:1733-1740.
89. Kreindler JL, Jackson AD, Kemp PA, Bridges RJ, Danahay H. Inhibition of chloride secretion in human bronchial epithelial cells by cigarette smoke extract. Am J Physiol (Lung Cell Mol Physiol) 2005; 288:L894-L902.
90. Gelbman BD, Heguy A, O'Connor TP, Zabner J, Crystal RG. Upregulation of pirin expression by chronic cigarette smoking is associated with bronchial epithelial cell apoptosis. Respir Res 2007; 8:10.
91. Pesci A, Majori M, Cuomo A, Borciani N, Bertacco S, Cacciani G, Gabrielli M. Neutrophils infiltrating bronchial epithelium in chronic obstructive pulmonary disease. Respir Med 1998; 92:863-870.
92. Takizawa H TM, Takami K, Ohtoshi T, Ito K, Satoh M, Okada Y, Yamasawa F, Nakahara K, Umeda A. Increased expression of transforming growth factor-beta1 in small airway epithelium from tobacco smokers and patients with chronic obstructive pulmonary disease (COPD). Am J Respir Crit Care Med 2001; 163:1476-1483.
93. Puchelle E, Zahm JM, Tournier JM, Coraux C. Airway epithelial repair, regeneration, and remodeling after injury in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006; 3:726-733.
94. Caramori G, Ito K, Contoli M, Di Stefano A, Johnston SL, Adcock IM, Papi A. Molecular mechanisms of respiratory virus-induced asthma and COPD exacerbations and pneumonia. Curr Med Chem 2006; 13:2267-2290.
95. Beem M, Egerer R, Anderson J. Respiratory syncytial virus neturalizing antibodies in persons residing in Chicago, Illinois. Pediatrics 1964; 34:761-770.
96. Welliver RC, Kaul TN, Putnam TI, Sun M, Riddlesberger K, Ogra PL. The antibody response to primary and secondary infection with respiratory syncytial virus: kinetics of class-specific responses. J Pediatr 1980; 96:808-813.
97. Glezen WP, Paredes A, Allison JE, Taber LH, Frank AL. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. J Pediatr 1981; 98:708-715.
98. de Sierra TM, Kumar ML, Wasser TE, Murphy BR, Subbarao EK. Respiratory syncytial virus-specific immunoglobulins in preterm infants. J Pediatr 1993; 122:787-791.
99. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998; 102:531-537.
100. Piedra PA, Jewell AM, Cron SG, Atmar RL, Glezen WP. Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies. Vaccine 2003; 21:3479-3482.
101. Walsh EE, Falsey AR. Age related differences in humoral immune response to respiratory syncytial virus infection in adults. J Med Virol 2004; 73:295-299.
102. Walsh EE, Falsey AR. Humoral and mucosal immunity in protection from natural respiratory syncytial virus infection in adults. J Infect Dis 2004; 190:373-378.
103. Falsey AR, Singh HK, Walsh EE. Serum antibody decay in adults following natural respiratory syncytial virus infection. JMed Virol 2006; 78:1493-1497.
104. Meyer KC. Aging. Proc Am Thorac Soc 2005; 2:433-439.
105. Hall CB, Powell KR, MacDonald NE, Gala CL, Menegus ME, Suffin SC, Cohen HJ. Respiratory syncytial viral infection in children with compromised immune function. N Eng J Med 1986; 315:77-81.
106. Zhang Y, Wang Y, Gilmore X, Xu K, Wyde PR, Mbawuike IN. An aged mouse model for RSV infection and diminished CD8(+) CTL responses. Exp Biol Med 2002; 227:133-140.
107. Liu B, Kimura Y. Local immune response to respiratory syncytial virus infection is diminished in senescence-accelerated mice. J Gen Virol 2007; 88:2552-2558.
108. Mbawuike IN, Wells J, Byrd R, Cron SG, Glezen WP, Piedra PA. HLA-restricted CD8+ cytotoxic T lymphocyte, interferon-gamma, and interleukin-4 responses to respiratory syncytial virus infection in infants and children. J Infect Dis 2001; 183:687-696.
109. de Bree GJ, Heidema J, van Leeuwen EM, van Bleek GM, Jonkers RE, Jansen HM, van Lier RA, Out TA. Respiratory syncytial virus-specific CD8+ memory T cell responses in elderly persons. J Infect Dis 2005; 191:1710-1718.
110. Looney RJ, Falsey AR, Walsh E, Campbell D. Effect of aging on cytokine production in response to respiratory syncytial virus infection. J Infect Dis 2002; 185:682-685.
111. Lee FE, Walsh EE, Falsey AR, Liu N, Liu D, Divekar A, Snyder-Cappione JE, Mosmann TR. The balance between influenza- and RSV-specific CD4 t cells secreting IL-10 or IFNgamma in young and healthy-elderly subjects. Mech Ageing Dev 2005; 126:1223-1229.
112. Linton PJ, Dorshkind K. Age-related changes in lymphocyte development and function. Nat Immunol 2004; 5:133-139.
113. de Bree GJ, Daniels H, Schilfgaarde M, Jansen HM, Out TA, van Lier RA, Jonkers RE. Characterization of CD4+ memory T cell responses directed against common respiratory pathogens in peripheral blood and lung. J Infect Dis 2007; 195:1718-1725.
114. Hancock A, Armstrong L, Gama R, Millar A. Production of interleukin 13 by alveolar macrophages from normal and fibrotic lung. Am J Respir Cell Mol Biol 1998; 18:60-65.
115. Wills-Karp M. Interleukin-13 in asthma pathogenesis. Immunol Rev 2004; 202:175-190.
116. Lee CG, Homer RJ, Zhu Z, Lanone S, Wang X, Koteliansky V, Shipley JM, Gotwals P, Noble P, Chen Q, Senior RM, Elias JA. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta (1). J Exp Med 2001; 194:809-821.
117. Ke B, Shen XD, Zhai Y, Gao F, Busuttil RW, Volk HD, Kupiec-Weglinski JW. Heme oxygenase 1 mediates the immunomodulatory and antiapoptotic effects of interleukin 13 gene therapy in vivo and in vitro. Hum Gene Ther 2002; 13:1845-1857.
118. Wynn TA. IL-13 effector functions. Annu Rev Immunol 2003; 21:425-456.
119. Zhou W, Hashimoto K, Moore ML, Elias JA, Zhu Z, Durbin J, Colasurdo G, Rutigliano JA, Chiappetta CL, Goleniewska K, O'Neal JF, Graham BS, Peebles RS. IL-13 is associated with reduced illness and replication in primary respiratory syncytial virus infection in the mouse. Microbes Infect 2006; 8:2880-2889.
120. Ermers MJ, Hoebee B, Hodemaekers HM, Kimman TG, Kimpen JL, Bont L. IL-13 genetic polymorphism identifies children with late wheezing after respiratory syncytial virus infection. J Allergy Clin Immunol 2007; 119:1086-1091.
121. Boutten A, Bonay M, Laribe S, Leseche G, Castier Y, Leçon-Malas V, Fournier M, Durand G, Aubier M, Dehoux M, Crestani B. Decreased expression of interleukin 13 in human lung emphysema. Thorax 2004; 59:850-854.
122. Mufson MA, Örvell C, Rafnar B, Norrby E. Two distinct subtypes of human respiratory syncytial virus. J Gen Virol 1985; 66:2111-2124.
123. Lukacs NW, Moore ML, Rudd BD, Berlin AA, Collins RD, Olson SJ, Ho SB, Peebles RS. Differential immune responses and pulmonary pathophysiology are induced by two different strains of respiratory syncytial virus. Am J Pathol 2006; 169:977-986.
124. Fodha I, Vabret A, Ghedira L, Seboui H, Chouchane S, Dewar J, Gueddiche N, Trabelsi A, Boujaafar N, Freymuth F. Respiratory syncytial virus infections in hospitalized infants: association between viral load, virus subgroup, and disease severity. J Med Virol 2007; 79:1951-1958.
125. Plotkowski MC, Puchelle E, Beck G, Jacquot J, Hannoun C. Adherence of type I Streptococcus pneumoniae to tracheal epithelium of mice infected with influenza A/PR8 virus. Am Rev Respir Dis 1986; 134:1040-1044.
126. Avadhanula V, Rodriguez CA, Devincenzo JP, Wang Y, Webby RJ, Ulett GC, Adderson EE. Respiratory viruses augment the adhesion of bacterial pathogens to respiratory epithelium in a viral species- and cell type-dependent manner. J Virol 2006; 80:1629-1636.
127. Avadhanula V, Wang Y, Portner A, Adderson E. Nontypeable Haemophilus influenzae and Streptococcus pneumoniae bind respiratory syncytial virus glycoprotein. J Med Microbiol 2007; 56:1133-1137.
128. Corbeil LB, Arnold KF, Kimball R, Berghaus L, Gershwin LJ. Specificity of IgG and IgE antibody responses to Haemophilus somnus infection of calves. Vet Immunol Immunopathol 2006; 113:191-199.
129. Monso E, Ruiz J, Rosell A, Manterola J, Fiz J, Morera J, Ausina V. Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush. Am J Respir Crit Care Med 1995; 152:1316-1320.
130. Cabello H, Torres A, Celis R, El-Ebiary M, Puig de la Bellacasa J, Xaubet A, Gonzalez J, Agusti C, Soler N. Bacterial colonization of distal airways in healthy subjects and chronic lung disease: A bronchoscopic study. Eur Respir J 1997; 10:1137-1144.
131. Zalacain R, Sobradillo V, Amilibia J, Barron J, Achotegui V, Pijoan JI, Llorente JL. Predisposing factors to bacterial colonization in chronic obstructive pulmonary disease. Eur Respir J 1999; 13:343-348.
132. Soler N, Ewig S, Torres A, Filella X, Gonzalez J, Zaubet A. Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease. Eur Respir J 1999; 14:1015-1022.
133. Hill AT, Campbell EJ, Hill SL, Bayley DL, Stockley RA. Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. Am J Med 2000; 109:288-295.
134. Chin CL, Manzel LJ, Lehman EE, Humlicek AL, Shi L, Starner TD, Denning GM, Murphy TF, Sethi S, Look DC. Haemophilus influenzae from patients with chronic obstructive pulmonary disease exacerbation induce more inflammation than colonizers. Am J Respir Crit Care Med 2005; 172:85-91.
135. Sajjan US, Jia Y, Newcomb DC, Bentley JK, Lukacs NW, LiPuma JJ, Hershenson MB. H. influenzae potentiates airway epithelial cell responses to rhinovirus by increasing ICAM-1 and TLR3 expression. FASEB J 2006; 20:2121-2123.
136. Wilkinson TM, Hurst JR, Perera WR, Wilks M, Donaldson GC, Wedzicha JA. Effect of interactions between lower airway bacterial and rhinoviral infection in exacerbations of COPD. Chest 2006; 129:317-324.
137. Sethi S. Coinfection in exacerbations of COPD: a new frontier. Chest 2006; 129:223-224.
138. Donaldson GC, Seemungal TA, Patel IS, Lloyd-Owen SJ, Wilkinson TM, Wedzicha JA. Longitudinal changes in the nature, severity and frequency of COPD exacerbations. Eur Respir J 2003; 22:931-936.